Ticker brief
FULC
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
+0.45
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
· daily mean sentiment, 2026-08-17 → 2026-08-17 · now +0.48 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | -0.57 | 1 | +0.40 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @theflynews | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.50 |
| @fwpharma | B | +0.98 | 1 | +0.50 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-17 | @fwpharma | +0.50 | Slate and Fulcrum line up a reverse merger to fund Slate's migraine portfolio. | · | tweet ↗ |
| 2026-08-17 | @BiopharmIQ | +0.50 | Biotech news list reports FDA acceptance, positive trials, a merger, placement and severe data-related move. | · | tweet ↗ |
| 2026-08-17 | @theflynews | +0.50 | Reports Fulcrum Therapeutics and Slate Medicines combining in an all-stock deal. | · | tweet ↗ |
| 2026-08-17 | @OpenOutcrier | +0.50 | Fulcrum Therapeutics and Slate Medicines announced a merger agreement. | · | tweet ↗ |
| 2026-08-17 | @PersimmonTI | +0.40 | Fulcrum will combine with Slate in a reverse merger backed by a $245M private placement. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.